100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant R44EY030828
Award Date
8/1/20
Completion Date
7/31/24
Dollars Obligated
$3.6M
Overview
Activity
9
Transactions
9
Subawards
Similar Awards
Federal Agency
National Eye Institute
Awardee
Aptitude Medical Systems Inc. (NWWEFYLD9JC3)
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
California, USA
Update #1
Update #2
TARGETING SDF-1 FOR EFFECTIVE WET AMD TREATMENT
Posted 9/17/19
5
1
2
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
TARGETING SDF-1 FOR EFFECTIVE WET AMD TREATMENT - PROJECT ABSTRACT WET AGE-RELATED MACULAR DEGENERATION (AMD) IS THE LEADING CAUSE OF NEW BLINDNESS AMONG PEOPLE WHO ARE 55 OR OLDER. THE CURRENT STANDARD OF CARE FOR WET AMD IS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENTS, SUCH AS LUCENTIS, EYLEA, AND AVASTIN (USED OFF-LABEL). THESE ANTI-VEGF AGENTS INHIBIT VEGF-MEDIATED ANGIOGENESIS, AND EFFECTIVELY STOP OR EVEN REVERSE THE VISION LOSS FOR MOST PATIENTS. DESPITE BEING THE BEST TREATMENT CURRENTLY AVAILABLE, IT HAS TWO CRITICAL SHORTCOMINGS: 1) LIMITED NEAR-TERM VISION GAIN AND POOR LONG- TERM VISION MAINTENANCE; (2) MAJOR COST AND TREATMENT BURDEN. FIRST, DESPITE CONTINUED TREATMENT, ONLY ~1/3 OF THE PATIENT GAIN >3 LINES OF VISION OVER THE FIRST 12 MONTHS; AFTER 3-4 YEARS, MOST PATIENTS START LOSING VISION AGAIN AND EVENTUALLY DROPPING TO PRE-TREATMENT LEVELS. SECOND, PATIENTS MUST RETURN TO THE CLINIC EVERY 1 TO 2 MONTHS FOR INTRAVITREAL INJECTIONS - A SPECIALIZED, UNCOMFORTABLE AND COSTLY PROCEDURE THAT REPRESENTS SIGNIFICANT TREATMENT BURDEN. THE PURPOSE OF THIS SBIR IS TO DEVELOP HIGHLY STABLE APTAMERS AGAINST SDF-1, WHICH MAY SERVE AS AN ORTHOGONAL TREATMENT FOR WET AMD. SDF-1 HAS LONG BEEN KNOWN TO PLAY AN IMPORTANT ROLE IN CHOROIDAL NEOVASCULARIZATION (CNV), THE LANDMARK PATHOLOGICAL PROCESS OF WET AMD. THE APTITUDE TEAM HAS ACCUMULATED EXTENSIVE EXPERIENCE IN APTAMER DISCOVERY. WE HAVE PREVIOUSLY DEVELOPED THE PARTICLE DISPLAY METHOD THAT SIGNIFICANTLY IMPROVES THE APTAMER PERFORMANCE. MOREOVER, WE HAVE MADE FURTHER IMPROVEMENT TO DIRECTLY SCREEN FOR FULLY MODIFIED APTAMERS THAT ENABLES LONGER DURATION OF EFFICACY. OUR EXPERTISE IN APTAMER DISCOVERY IS COMPLEMENTED BY OUR COLLABORATORS' EXPERTISE IN WET AMD PRECLINICAL RESEARCH. OUR COLLABORATOR IS AMONG THE FIRST TO DEMONSTRATE THE ROLE OF SDF-1 IN CNV, AND POSSESS IN-DEPTH EXPERTISE IN RELEVANT ANIMAL MODELS. IF SUCCESSFUL, THIS PROJECT HAS THE POTENTIAL OF BRINGING MORE EFFICACIOUS AND AFFORDABLE TREATMENT TO WET AMD PATIENTS.
($55k)
3/18/25
Not listed
TARGETING SDF-1 FOR EFFECTIVE WET AMD TREATMENT - PROJECT ABSTRACT WET AGE-RELATED MACULAR DEGENERATION (AMD) IS THE LEADING CAUSE OF NEW BLINDNESS AMONG PEOPLE WHO ARE 55 OR OLDER. THE CURRENT STANDARD OF CARE FOR WET AMD IS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENTS, SUCH AS LUCENTIS, EYLEA, AND AVASTIN (USED OFF-LABEL). THESE ANTI-VEGF AGENTS INHIBIT VEGF-MEDIATED ANGIOGENESIS, AND EFFECTIVELY STOP OR EVEN REVERSE THE VISION LOSS FOR MOST PATIENTS. DESPITE BEING THE BEST TREATMENT CURRENTLY AVAILABLE, IT HAS TWO CRITICAL SHORTCOMINGS: 1) LIMITED NEAR-TERM VISION GAIN AND POOR LONG- TERM VISION MAINTENANCE; (2) MAJOR COST AND TREATMENT BURDEN. FIRST, DESPITE CONTINUED TREATMENT, ONLY ~1/3 OF THE PATIENT GAIN >3 LINES OF VISION OVER THE FIRST 12 MONTHS; AFTER 3-4 YEARS, MOST PATIENTS START LOSING VISION AGAIN AND EVENTUALLY DROPPING TO PRE-TREATMENT LEVELS. SECOND, PATIENTS MUST RETURN TO THE CLINIC EVERY 1 TO 2 MONTHS FOR INTRAVITREAL INJECTIONS - A SPECIALIZED, UNCOMFORTABLE AND COSTLY PROCEDURE THAT REPRESENTS SIGNIFICANT TREATMENT BURDEN. THE PURPOSE OF THIS SBIR IS TO DEVELOP HIGHLY STABLE APTAMERS AGAINST SDF-1, WHICH MAY SERVE AS AN ORTHOGONAL TREATMENT FOR WET AMD. SDF-1 HAS LONG BEEN KNOWN TO PLAY AN IMPORTANT ROLE IN CHOROIDAL NEOVASCULARIZATION (CNV), THE LANDMARK PATHOLOGICAL PROCESS OF WET AMD. THE APTITUDE TEAM HAS ACCUMULATED EXTENSIVE EXPERIENCE IN APTAMER DISCOVERY. WE HAVE PREVIOUSLY DEVELOPED THE PARTICLE DISPLAY METHOD THAT SIGNIFICANTLY IMPROVES THE APTAMER PERFORMANCE. MOREOVER, WE HAVE MADE FURTHER IMPROVEMENT TO DIRECTLY SCREEN FOR FULLY MODIFIED APTAMERS THAT ENABLES LONGER DURATION OF EFFICACY. OUR EXPERTISE IN APTAMER DISCOVERY IS COMPLEMENTED BY OUR COLLABORATORS' EXPERTISE IN WET AMD PRECLINICAL RESEARCH. OUR COLLABORATOR IS AMONG THE FIRST TO DEMONSTRATE THE ROLE OF SDF-1 IN CNV, AND POSSESS IN-DEPTH EXPERTISE IN RELEVANT ANIMAL MODELS. IF SUCCESSFUL, THIS PROJECT HAS THE POTENTIAL OF BRINGING MORE EFFICACIOUS AND AFFORDABLE TREATMENT TO WET AMD PATIENTS.
$0
1/2/24
Not listed
TARGETING SDF-1 FOR EFFECTIVE WET AMD TREATMENT - PROJECT ABSTRACT WET AGE-RELATED MACULAR DEGENERATION (AMD) IS THE LEADING CAUSE OF NEW BLINDNESS AMONG PEOPLE WHO ARE 55 OR OLDER. THE CURRENT STANDARD OF CARE FOR WET AMD IS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENTS, SUCH AS LUCENTIS, EYLEA, AND AVASTIN (USED OFF-LABEL). THESE ANTI-VEGF AGENTS INHIBIT VEGF-MEDIATED ANGIOGENESIS, AND EFFECTIVELY STOP OR EVEN REVERSE THE VISION LOSS FOR MOST PATIENTS. DESPITE BEING THE BEST TREATMENT CURRENTLY AVAILABLE, IT HAS TWO CRITICAL SHORTCOMINGS: 1) LIMITED NEAR-TERM VISION GAIN AND POOR LONG- TERM VISION MAINTENANCE; (2) MAJOR COST AND TREATMENT BURDEN. FIRST, DESPITE CONTINUED TREATMENT, ONLY ~1/3 OF THE PATIENT GAIN >3 LINES OF VISION OVER THE FIRST 12 MONTHS; AFTER 3-4 YEARS, MOST PATIENTS START LOSING VISION AGAIN AND EVENTUALLY DROPPING TO PRE-TREATMENT LEVELS. SECOND, PATIENTS MUST RETURN TO THE CLINIC EVERY 1 TO 2 MONTHS FOR INTRAVITREAL INJECTIONS - A SPECIALIZED, UNCOMFORTABLE AND COSTLY PROCEDURE THAT REPRESENTS SIGNIFICANT TREATMENT BURDEN. THE PURPOSE OF THIS SBIR IS TO DEVELOP HIGHLY STABLE APTAMERS AGAINST SDF-1, WHICH MAY SERVE AS AN ORTHOGONAL TREATMENT FOR WET AMD. SDF-1 HAS LONG BEEN KNOWN TO PLAY AN IMPORTANT ROLE IN CHOROIDAL NEOVASCULARIZATION (CNV), THE LANDMARK PATHOLOGICAL PROCESS OF WET AMD. THE APTITUDE TEAM HAS ACCUMULATED EXTENSIVE EXPERIENCE IN APTAMER DISCOVERY. WE HAVE PREVIOUSLY DEVELOPED THE PARTICLE DISPLAY METHOD THAT SIGNIFICANTLY IMPROVES THE APTAMER PERFORMANCE. MOREOVER, WE HAVE MADE FURTHER IMPROVEMENT TO DIRECTLY SCREEN FOR FULLY MODIFIED APTAMERS THAT ENABLES LONGER DURATION OF EFFICACY. OUR EXPERTISE IN APTAMER DISCOVERY IS COMPLEMENTED BY OUR COLLABORATORS' EXPERTISE IN WET AMD PRECLINICAL RESEARCH. OUR COLLABORATOR IS AMONG THE FIRST TO DEMONSTRATE THE ROLE OF SDF-1 IN CNV, AND POSSESS IN-DEPTH EXPERTISE IN RELEVANT ANIMAL MODELS. IF SUCCESSFUL, THIS PROJECT HAS THE POTENTIAL OF BRINGING MORE EFFICACIOUS AND AFFORDABLE TREATMENT TO WET AMD PATIENTS.
$0
1/2/24
Not listed
TARGETING SDF-1 FOR EFFECTIVE WET AMD TREATMENT - PROJECT ABSTRACT WET AGE-RELATED MACULAR DEGENERATION (AMD) IS THE LEADING CAUSE OF NEW BLINDNESS AMONG PEOPLE WHO ARE 55 OR OLDER. THE CURRENT STANDARD OF CARE FOR WET AMD IS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENTS, SUCH AS LUCENTIS, EYLEA, AND AVASTIN (USED OFF-LABEL). THESE ANTI-VEGF AGENTS INHIBIT VEGF-MEDIATED ANGIOGENESIS, AND EFFECTIVELY STOP OR EVEN REVERSE THE VISION LOSS FOR MOST PATIENTS. DESPITE BEING THE BEST TREATMENT CURRENTLY AVAILABLE, IT HAS TWO CRITICAL SHORTCOMINGS: 1) LIMITED NEAR-TERM VISION GAIN AND POOR LONG- TERM VISION MAINTENANCE; (2) MAJOR COST AND TREATMENT BURDEN. FIRST, DESPITE CONTINUED TREATMENT, ONLY ~1/3 OF THE PATIENT GAIN >3 LINES OF VISION OVER THE FIRST 12 MONTHS; AFTER 3-4 YEARS, MOST PATIENTS START LOSING VISION AGAIN AND EVENTUALLY DROPPING TO PRE-TREATMENT LEVELS. SECOND, PATIENTS MUST RETURN TO THE CLINIC EVERY 1 TO 2 MONTHS FOR INTRAVITREAL INJECTIONS - A SPECIALIZED, UNCOMFORTABLE AND COSTLY PROCEDURE THAT REPRESENTS SIGNIFICANT TREATMENT BURDEN. THE PURPOSE OF THIS SBIR IS TO DEVELOP HIGHLY STABLE APTAMERS AGAINST SDF-1, WHICH MAY SERVE AS AN ORTHOGONAL TREATMENT FOR WET AMD. SDF-1 HAS LONG BEEN KNOWN TO PLAY AN IMPORTANT ROLE IN CHOROIDAL NEOVASCULARIZATION (CNV), THE LANDMARK PATHOLOGICAL PROCESS OF WET AMD. THE APTITUDE TEAM HAS ACCUMULATED EXTENSIVE EXPERIENCE IN APTAMER DISCOVERY. WE HAVE PREVIOUSLY DEVELOPED THE PARTICLE DISPLAY METHOD THAT SIGNIFICANTLY IMPROVES THE APTAMER PERFORMANCE. MOREOVER, WE HAVE MADE FURTHER IMPROVEMENT TO DIRECTLY SCREEN FOR FULLY MODIFIED APTAMERS THAT ENABLES LONGER DURATION OF EFFICACY. OUR EXPERTISE IN APTAMER DISCOVERY IS COMPLEMENTED BY OUR COLLABORATORS' EXPERTISE IN WET AMD PRECLINICAL RESEARCH. OUR COLLABORATOR IS AMONG THE FIRST TO DEMONSTRATE THE ROLE OF SDF-1 IN CNV, AND POSSESS IN-DEPTH EXPERTISE IN RELEVANT ANIMAL MODELS. IF SUCCESSFUL, THIS PROJECT HAS THE POTENTIAL OF BRINGING MORE EFFICACIOUS AND AFFORDABLE TREATMENT TO WET AMD PATIENTS.
$805.2k
7/28/21
Not listed
TARGETING SDF-1 FOR EFFECTIVE WET AMD TREATMENT - PROJECT ABSTRACT WET AGE-RELATED MACULAR DEGENERATION (AMD) IS THE LEADING CAUSE OF NEW BLINDNESS AMONG PEOPLE WHO ARE 55 OR OLDER. THE CURRENT STANDARD OF CARE FOR WET AMD IS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AGENTS, SUCH AS LUCENTIS, EYLEA, AND AVASTIN (USED OFF-LABEL). THESE ANTI-VEGF AGENTS INHIBIT VEGF-MEDIATED ANGIOGENESIS, AND EFFECTIVELY STOP OR EVEN REVERSE THE VISION LOSS FOR MOST PATIENTS. DESPITE BEING THE BEST TREATMENT CURRENTLY AVAILABLE, IT HAS TWO CRITICAL SHORTCOMINGS: 1) LIMITED NEAR-TERM VISION GAIN AND POOR LONG- TERM VISION MAINTENANCE; (2) MAJOR COST AND TREATMENT BURDEN. FIRST, DESPITE CONTINUED TREATMENT, ONLY ~1/3 OF THE PATIENT GAIN >3 LINES OF VISION OVER THE FIRST 12 MONTHS; AFTER 3-4 YEARS, MOST PATIENTS START LOSING VISION AGAIN AND EVENTUALLY DROPPING TO PRE-TREATMENT LEVELS. SECOND, PATIENTS MUST RETURN TO THE CLINIC EVERY 1 TO 2 MONTHS FOR INTRAVITREAL INJECTIONS - A SPECIALIZED, UNCOMFORTABLE AND COSTLY PROCEDURE THAT REPRESENTS SIGNIFICANT TREATMENT BURDEN. THE PURPOSE OF THIS SBIR IS TO DEVELOP HIGHLY STABLE APTAMERS AGAINST SDF-1, WHICH MAY SERVE AS AN ORTHOGONAL TREATMENT FOR WET AMD. SDF-1 HAS LONG BEEN KNOWN TO PLAY AN IMPORTANT ROLE IN CHOROIDAL NEOVASCULARIZATION (CNV), THE LANDMARK PATHOLOGICAL PROCESS OF WET AMD. THE APTITUDE TEAM HAS ACCUMULATED EXTENSIVE EXPERIENCE IN APTAMER DISCOVERY. WE HAVE PREVIOUSLY DEVELOPED THE PARTICLE DISPLAY METHOD THAT SIGNIFICANTLY IMPROVES THE APTAMER PERFORMANCE. MOREOVER, WE HAVE MADE FURTHER IMPROVEMENT TO DIRECTLY SCREEN FOR FULLY MODIFIED APTAMERS THAT ENABLES LONGER DURATION OF EFFICACY. OUR EXPERTISE IN APTAMER DISCOVERY IS COMPLEMENTED BY OUR COLLABORATORS' EXPERTISE IN WET AMD PRECLINICAL RESEARCH. OUR COLLABORATOR IS AMONG THE FIRST TO DEMONSTRATE THE ROLE OF SDF-1 IN CNV, AND POSSESS IN-DEPTH EXPERTISE IN RELEVANT ANIMAL MODELS. IF SUCCESSFUL, THIS PROJECT HAS THE POTENTIAL OF BRINGING MORE EFFICACIOUS AND AFFORDABLE TREATMENT TO WET AMD PATIENTS.
$805.2k
7/28/21